Ocular irritation from high-dose methotrexate therapy: Pharmacokinetics of drug in the tear film
- 15 November 1981
- Vol. 48 (10) , 2158-2162
- https://doi.org/10.1002/1097-0142(19811115)48:10<2158::aid-cncr2820481007>3.0.co;2-i
Abstract
Four of 13 patients receiving intermittent high-dose methotrexate therapy experienced recurrent symptoms of ocular irritation (burning, pruritus, “dry eyes”) two to seven days after chemotherapy. Ophthalmic examination was unremarkable in symptomatic individuals except for decreased reflex production of tears in some patients. Pharmacokinetic studies of a group of these patients revealed concentrations of methotrexate in tears equivalent to those in plasma at 24 and 48 hours after treatment; these concentrations reached 1 × 10−5 M during the infusion of methotrexate. The occurrence of acidic lacrimal secretions, pH 6.5 in one symptomatic patient, may have contributed to decreased solubility of methotrexate in the fluid of the conjunctival sac.This publication has 12 references indexed in Scilit:
- Chapter 2. Pharmacology of the Conjunctival SacPublished by S. Karger AG ,2015
- Tear-Duct Fibrosis (Dacryostenosis) Due to 5-FluorouracilAnnals of Internal Medicine, 1978
- Effect of pleural effusion on high‐dose methotrexate kineticsClinical Pharmacology & Therapeutics, 1978
- Clinical Pharmacokinetics of Methotrexate1Clinical Pharmacokinetics, 1978
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977
- Competitive protein binding assay for methotrexate.Proceedings of the National Academy of Sciences, 1975
- New Approaches to Cancer Chemotherapy with MethotrexateNew England Journal of Medicine, 1975
- Threshold Methotrexate Concentration for In Vivo Inhibition of DNA Synthesis in Normal and Tumorous Target TissuesJournal of Clinical Investigation, 1973
- Metastatic Uveal ChoriocarcinomaArchives of Ophthalmology (1950), 1970